Abbott Laboratories (NYSE: ABT) is a global healthcare company headquartered in Abbott Park, Illinois, with significant operations in neuromodulation, including deep brain stimulation (DBS) systems for the treatment of movement disorders like [Parkinson's disease](/diseases/parkinsons-disease). Founded in 1888, Abbott is one of the largest healthcare companies in the world with a market capitalization of approximately $220 billion and annual revenues exceeding $40 billion[@abbotta].
Corporate Overview
Abbott operates across multiple healthcare segments:
Diagnostics — Point-of-care and laboratory testing systems
Medical Devices — Vascular, diabetes, and neuromodulation products
Nutritional Products — Pediatric and adult nutritional supplements
Established Pharmaceuticals — Generic and specialty pharmaceuticals
The neuromodulation division, Abbott Neuromodulation, represents a strategic growth platform focused on implantable devices for treating neurological conditions. The company has invested heavily in developing next-generation neurostimulation technologies that offer improved patient outcomes and reduced side effects compared to earlier-generation devices[@abbott].
Neuromodulation Portfolio
Infinity DBS System
The Infinity Deep Brain Stimulation System is Abbott's flagship product for treating movement disorders. Approved by the FDA and regulatory bodies worldwide, Infinity represents a significant advancement in DBS technology:
...
Abbott Laboratories (NYSE: ABT) is a global healthcare company headquartered in Abbott Park, Illinois, with significant operations in neuromodulation, including deep brain stimulation (DBS) systems for the treatment of movement disorders like [Parkinson's disease](/diseases/parkinsons-disease). Founded in 1888, Abbott is one of the largest healthcare companies in the world with a market capitalization of approximately $220 billion and annual revenues exceeding $40 billion[@abbotta].
Corporate Overview
Abbott operates across multiple healthcare segments:
Diagnostics — Point-of-care and laboratory testing systems
Medical Devices — Vascular, diabetes, and neuromodulation products
Nutritional Products — Pediatric and adult nutritional supplements
Established Pharmaceuticals — Generic and specialty pharmaceuticals
The neuromodulation division, Abbott Neuromodulation, represents a strategic growth platform focused on implantable devices for treating neurological conditions. The company has invested heavily in developing next-generation neurostimulation technologies that offer improved patient outcomes and reduced side effects compared to earlier-generation devices[@abbott].
Neuromodulation Portfolio
Infinity DBS System
The Infinity Deep Brain Stimulation System is Abbott's flagship product for treating movement disorders. Approved by the FDA and regulatory bodies worldwide, Infinity represents a significant advancement in DBS technology:
Directional leads — Unlike traditional ring electrodes, directional leads allow clinicians to precisely target specific brain regions while minimizing stimulation of off-target areas that can cause side effects such as speech disturbances or cognitive changes.
MRI compatibility — Full-body MRI conditional labeling allows patients to safely undergo MRI scans post-implant, expanding diagnostic options for aging populations who frequently require imaging.
Wireless connectivity — The system features Bluetooth-enabled patient controllers and clinician programmers, enabling remote adjustments and simplified in-office programming sessions.
Recharge and non-recharge options — Patients can choose between devices with replaceable batteries (typically lasting 3-5 years) or rechargeable systems that offer longer device life with daily or weekly charging.
Proclaim XR Spinal Cord Stimulation System
While not specific to neurodegeneration, the Proclaim XR system represents Abbott's broader neuromodulation capabilities. The SCS system is approved for chronic pain management and uses similar technology to their DBS platform, demonstrating the company's platform approach to neurostimulation.
Proclaim DBS System
Abbott's next-generation DBS system, the Proclaim DBS, builds on the Infinity platform with enhanced features:
Improved battery technology — Longer-lasting rechargeable batteries with faster charging times
Expanded programming options — More granular control over stimulation parameters
Clinical Evidence
Deep brain stimulation with Abbott systems has demonstrated significant clinical benefits in multiple randomized controlled trials and real-world studies:
Motor symptom reduction — 40-60% reduction in tremor, rigidity, and bradykinesia scores
ON/OFF time improvement — Increased "ON" time without troublesome dyskinesia
Medication reduction — Significant decrease in levodopa requirements post-implant
Quality of life — Documented improvements in PDQ-39 and other quality of life measures[@dbs2018]
Research and Development
Abbott invests significantly in neuromodulation R&D, with active programs in:
Next-Generation DBS
Closed-loop sensing — Developing systems that can detect biomarkers and automatically adjust stimulation
Adaptive stimulation algorithms — Real-time modulation based on patient activity and symptom state
Novel target identification — Exploring new brain targets for psychiatric indications
Alzheimer's Disease Investigation
Abbott has explored DBS for cognitive enhancement in Alzheimer's disease through the Viviani/Proclaim DBS program. While still investigational, this represents a potential future application of their technology beyond movement disorders. Early studies have targeted brain regions involved in memory and cognition, though clinical evidence remains preliminary.
Peripheral Nerve Stimulation
Research into peripheral nerve stimulation for various indications expands the company's pipeline beyond CNS applications.
Market Position
Abbott is one of three major players in the global DBS market:
Abbott's neuromodulation business represents a strategic priority as the company seeks growth beyond traditional medical device markets. Key strategic drivers include:
Aging population — Growing demand for treatments for movement disorders as global populations age
Technology differentiation — Continuous innovation in directional leads and sensing capabilities
Geographic expansion — Increasing penetration in Asian and emerging markets
Pipeline expansion — Moving from movement disorders to psychiatric and cognitive indications